Radioactive drug targets tough prostate cancer
NCT ID NCT05691465
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a radioactive drug called lutetium Lu 177 dotatate in men with advanced prostate cancer that has neuroendocrine features. The drug seeks out and kills cancer cells that have a specific protein on their surface. The goal is to see if it can shrink tumors. About 35 men will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lutetium Lu 177 dotatate (a radioactive drug)
What this could lead to
If it works, this could offer a new treatment option for men with this hard-to-treat type of prostate cancer that has spread.
What could go wrong
This is a small, early-phase trial with only 35 participants. It may not work for everyone, and the radioactive drug can cause side effects like damage to healthy cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IVB PROSTATE CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Comprehensive Cancer Center
RECRUITINGDuarte, California, 91010, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Johns Hopkins University/Sidney Kimmel Cancer Center
RECRUITINGBaltimore, Maryland, 21287, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Los Angeles General Medical Center
RECRUITINGLos Angeles, California, 90033, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Northwestern University
RECRUITINGChicago, Illinois, 60611, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
USC / Norris Comprehensive Cancer Center
RECRUITINGLos Angeles, California, 90033, United States
Contact
Contact Phone: •••-•••-••••
-
UT MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UT Southwestern/Simmons Cancer Center-Dallas
SUSPENDEDDallas, Texas, 75390, United States
-
University of California Davis Comprehensive Cancer Center
ACTIVE_NOT_RECRUITINGSacramento, California, 95817, United States
-
University of Kentucky/Markey Cancer Center
RECRUITINGLexington, Kentucky, 40536, United States
Contact Phone: •••-•••-••••
Contact
-
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
RECRUITINGMadison, Wisconsin, 53718, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Wisconsin Carbone Cancer Center - University Hospital
RECRUITINGMadison, Wisconsin, 53792, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Wake Forest University Health Sciences
RECRUITINGWinston-Salem, North Carolina, 27157, United States
Contact
Contact Phone: •••-•••-••••